{"id":115200,"date":"2021-05-27T09:00:00","date_gmt":"2021-05-27T09:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2875132"},"modified":"2021-05-27T09:00:00","modified_gmt":"2021-05-27T09:00:00","slug":"igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others","status":"publish","type":"post","link":"http:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/","title":{"rendered":"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others"},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/IgG4-Related-Disease-Pipeline-Insights-Therapies-Therapeutics-Treatment-Medications-Drugs-Market-Epidemiology.jpg?1622090141966\" alt=\"IgG4-Related-Disease-Pipeline-Insights-Therapies-Therapeutics-Treatment-Medications-Drugs-Market-Epidemiology\" width=\"630\" height=\"326\" \/><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&rsquo;s <\/span><strong>IgG4 related Disease Pipeline Insights<\/strong><span style=\"font-weight: 400;\"> report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the IgG4 related Disease domain.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease Pipeline Analysis<\/strong><\/a><span style=\"font-weight: 400;\"> report offers a comprehensive outlay of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for IgG4 related Disease emerging therapies.&nbsp;<\/span><span style=\"font-weight: 400;\">The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.&nbsp;<\/span><\/p>\n<p><strong>Some of the key highlights from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease Pipeline<\/strong><\/a><strong> report:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">At present, there are no specific drugs available to cure the disease completely as the pathophysiology of the IgG4 related disease is not clear, however, research and development are going on to find effective therapeutics options against IgG4 related Disease.&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Currently, IgG4-related diseases exhibit a high medical unmet need, with many therapies in the pipeline the therapeutics market is expected to change significantly in the future.&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The prominent players strengthening the IgG4 related Disease pipeline include <\/span><strong>Viela Bio\/Horizon Therapeutics, Xencor, Principia Biopharma,<\/strong><span style=\"font-weight: 400;\"> and many others.&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The emerging therapies in the IgG4-related diseases market include <\/span><strong>Inebilizumab, Obexelimab, Rilzabrutinib, <\/strong><span style=\"font-weight: 400;\">and others. Few of the therapies are in the last stage of development and are expected to launch in the near future.&nbsp;<\/span><\/li>\n<\/ul>\n<p><strong>Request for Sample @ <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease Pipeline Insights and Outlook<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition with a characteristic histopathological appearance that can affect multiple organs of the body. It mostly affects middle-aged to elderly individuals, however, children can also be affected. Similarly, males are found to be more affected than females.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">There is no drug in the market to cure the disease, however, with many therapies in the pipeline the treatment scenario is expected to change in the coming years. As per, DelveInsight, the IgG4-Related Disease therapeutics market is further expected to increase in the coming future owing to factors such as rising prevalent population, technological advancements, and launch of potential therapies.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease Pipeline Analysis<\/strong><\/a><strong>: Drug Profile&nbsp;<\/strong><\/p>\n<ul>\n<li><strong>Inebilizumab: Viela Bio\/Horizon Therapeutics&nbsp;<br \/><\/strong>Inebilizumab is a humanized monoclonal antibody designed to target and deplete CD19-expressing B cells. In October 2020, Viela Bio initiated a Phase 3, randomized, double-blind, multicenter, and placebo-controlled study of Inebilizumab efficacy and safety in IgG4-Related Disease.<\/li>\n<\/ul>\n<ul>\n<li><strong>Rilzabrutinib: Principia Biopharma<br \/><\/strong>Principia Biopharma is working on Rilzabrutinib against three different disease indications (including IgG4-Related Disease). The therapy is currently in Phase II of the clinical stage. Rilzabrutinib against IgG4-RD can impact many of the driving features of the IgG4-Related Disease, including inflammation, allergic components, monocytes, macrophages, and B cells implicated in initiation and maintenance of disease.<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Dive deeper to know more @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease therapeutics and drugs pipeline<\/strong><\/a><\/p>\n<p><strong>Key Pipeline Therapies along with Companies&nbsp;<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Inebilizumab: <\/span><strong>Viela Bio\/Horizon Therapeutics<\/strong><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Rilzabrutinib: <\/span><strong>Principia Biopharma<\/strong><\/li>\n<\/ul>\n<p><strong>And few others<\/strong><\/p>\n<p><strong>IgG4 related Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul>\n<li><strong>By Product Type<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Monotherapy<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Combination Therapy&nbsp;<\/span><\/li>\n<\/ul>\n<\/ul>\n<ul>\n<li><strong>By Stage<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Discovery&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pre-clinical<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase I<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase II<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Phase III<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Pre-registration&nbsp;<\/span><\/li>\n<\/ul>\n<\/ul>\n<ul>\n<li><strong>By Route of Administration<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Oral<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Intravenous<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Inhalation<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Sub-cutaneous<\/span><\/li>\n<\/ul>\n<\/ul>\n<ul>\n<li><strong>By Molecule Type<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Small Molecule&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Gene Therapy<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Stem Cell Therapy&nbsp;<\/span><\/li>\n<\/ul>\n<\/ul>\n<ul>\n<li><strong>Targets:<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Protease<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Immunomodulatory<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Multiple Kinase Inhibitor<\/span><\/li>\n<\/ul>\n<\/ul>\n<ul>\n<li><strong>By Mechanism of Action<\/strong><\/li>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Anti-CD 19<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Fc gamma receptor IIB antagonists<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Agammaglobulinaemia tyrosine kinase inhibitors<\/span><\/li>\n<\/ul>\n<\/ul>\n<p><strong>Got queries? Reach out for more information @ <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease Drug Pipeline Assessment<\/strong><\/a><\/p>\n<p><strong>Scope of the Report<\/strong><\/p>\n<ul>\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Market Players: Viela Bio, Horizon Therapeutics, Principia Biopharma, Xencor, and others.<\/strong><\/li>\n<li><strong>Key Pipeline Therapies: Obexelimab, Inebilizumab, Rilzabrutinib, and others.<\/strong><\/li>\n<\/ul>\n<p><strong>Table of Content&nbsp;<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">1<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">2<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">3<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Current Treatment Patterns<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">4<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">5<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Therapeutic Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">6<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Late Stage Products (Phase-III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">7<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Mid Stage Products (Phase-II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">8<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Early Stage IgG4 related Disease Products (Phase-I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">9<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">10<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">11<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Dormant Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">12<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Discontinued Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">13<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Product Profiles<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">14<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">15<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">16<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Dormant and Discontinued Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">17<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">18<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Future Perspectives<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">19<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">IgG4 related Disease Analyst Review<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">20<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">21<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\"> Report Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Know more of what&rsquo;s covered in the <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease Pipeline Assessment<\/strong><\/a><span style=\"font-weight: 400;\"> report<\/span><\/p>\n<p><strong>Key Questions Answered in the IgG4 related Disease Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the current options for IgG4 related Disease treatment?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many companies are developing therapies for the treatment of IgG4 Related Diseases?&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the principal therapies developed by these companies in the industry?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many therapies are developed by each company for the treatment of IgG4 related Diseases?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many IgG4 related Disease emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of IgG4 related Disease?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the IgG4 related Disease market?&nbsp;<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Request for a Webex demo @ <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/igg4-related-disease-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4 related Disease Drug Pipeline<\/strong><\/a><span style=\"font-weight: 400;\"> and get a walk-through of our report<\/span><\/p>\n<p><strong>Related Reports &#8211;<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/igg4-related-disease-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4-Related Disease Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217; s IgG4-Related Disease- Market Insights, Epidemiology and Market Forecast &#8211; 2030 report provides a detailed understanding of historical and forecasted epidemiology as well as the market forecast in the 7MM.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/igg4-related-disease-epidemiology-forecast?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>IgG4-Related Disease Epidemiology Forecast<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s IgG4-Related Disease &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of IgG4-Related Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/guillain-barre-syndrome-gbs-market\"><strong>Guillain-Barre Syndrome (GBS) Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Guillain-Barre Syndrome (GBS) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Guillain-Barre Syndrome (GBS) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuromodulation-devices-market\"><strong>Neuromodulation Devices Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&rsquo;s &lsquo;Neuromodulation Devices -Market Insights, Competitive Landscape, and Market Forecast &#8211; 2026&rsquo; report delivers an in-depth understanding of Neuromodulation Devices and the historical and forecasted Neuromodulation Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/span><\/p>\n<p><strong>Healthcare Blogs By DelveInsight &#8211;&nbsp;<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/complex-regional-pain-syndrome-treatment-therapies\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>CRPS Treatments<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/complex-regional-pain-syndrome-treatment-therapies\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Neridronate FDA<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/medical-marijuana-clinical-trials\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Marijuana Clinical Trials<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/opioid-withdrawal-syndrome-pipeline\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Opiate Withdrawal Cocktail<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/substance-use-disorder-sud-treatment-market\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><strong>Substance Use Disorder Market<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/chronic-respiratory-disease-crd-prevalence-and-treatment-options\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\"><strong>Chronic Respiratory Diseases (CRD) Treatment Market<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/antibody-mediated-rejection-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\"><strong>Antibody-mediated Rejection Therapeutics Market&nbsp;<\/strong><\/a><\/p>\n<p><strong>About <\/strong><a href=\"https:\/\/www.delveinsight.com\/\"><strong>DelveInsight<\/strong><\/a><br \/><span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform <\/span><a href=\"https:\/\/www.delveinsight.com\/pharmdelve\"><strong>PharmDelve<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"><strong>Connect With Us at&nbsp;<\/strong><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\"><strong>LinkedIn<\/strong><\/a><strong>&nbsp;|<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\"><strong>&nbsp;Facebook<\/strong><\/a><strong>&nbsp;|<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\"><strong>&nbsp;Twitter<\/strong><\/a><\/span><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/igg4\/\" rel=\"tag\">IgG4<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/igg4-related-disease\/\" rel=\"tag\">IgG4-Related Disease<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/igg4-related-disease-pipeline\/\" rel=\"tag\">IgG4 related Disease Pipeline<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.delveinsight.com\/<\/a><br \/><b>Contact Information:<\/b><br \/>Shruti Thakur \u00a0 info@delveinsight.com\u00a0 +1(919)321-6187\u00a0 <\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/icn-internal-distribution\/\" rel=\"category tag\">iCN Internal Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Shruti Thakur \u00a0<br \/> info@delveinsight.com\u00a0 <br \/> +1(919)321-6187\u00a0 <\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\">IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s IgG4 related Disease Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the IgG4 related Disease domain. The IgG4 related Disease Pipeline Analysis report offers a comprehensive outlay [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\">IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"http:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-115200","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others - Business\" \/>\n<meta property=\"og:description\" content=\"DelveInsight&rsquo;s IgG4 related Disease Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the IgG4 related Disease domain. The IgG4 related Disease Pipeline Analysis report offers a comprehensive outlay [&hellip;] The post IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\",\"name\":\"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"datePublished\":\"2021-05-27T09:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"http:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/","og_locale":"en_US","og_type":"article","og_title":"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others - Business","og_description":"DelveInsight&rsquo;s IgG4 related Disease Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the IgG4 related Disease domain. The IgG4 related Disease Pipeline Analysis report offers a comprehensive outlay [&hellip;] The post IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/","og_site_name":"Business","article_published_time":"2021-05-27T09:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/","url":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/","name":"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","datePublished":"2021-05-27T09:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2021\/05\/27\/igg4-related-disease-therapeutics-market-to-anticipate-a-positive-shift-owing-to-the-launch-of-therapies-by-key-players-including-viela-bio-horizon-therapeutics-principia-biopharma-and-others\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"IgG4 Related Disease Therapeutics Market to Anticipate a Positive Shift Owing to the Launch of Therapies by Key Players including Viela Bio, Horizon Therapeutics, Principia Biopharma, and Others"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"http:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/115200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=115200"}],"version-history":[{"count":1,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/115200\/revisions"}],"predecessor-version":[{"id":115201,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/115200\/revisions\/115201"}],"wp:attachment":[{"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=115200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=115200"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=115200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}